Histogenics (NASDAQ:HSGX) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.
A number of other brokerages have also recently issued reports on HSGX. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Histogenics in a research report on Monday, March 19th. Zacks Investment Research upgraded shares of Histogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th.
Histogenics traded down $0.08, reaching $2.07, during midday trading on Thursday, according to Marketbeat Ratings. 120,500 shares of the company’s stock were exchanged, compared to its average volume of 112,164. The stock has a market cap of $61.68 million, a P/E ratio of -2.11 and a beta of 1.69. Histogenics has a 1-year low of $2.18 and a 1-year high of $2.20.
Institutional investors and hedge funds have recently made changes to their positions in the business. Sabby Management LLC raised its position in Histogenics by 98.3% during the fourth quarter. Sabby Management LLC now owns 955,060 shares of the biotechnology company’s stock worth $1,958,000 after acquiring an additional 473,393 shares during the last quarter. Virtu Financial LLC raised its position in shares of Histogenics by 413.4% in the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 51,182 shares during the last quarter. Bradley Foster & Sargent Inc. CT acquired a new position in shares of Histogenics in the first quarter valued at approximately $199,000. Renaissance Technologies LLC raised its position in shares of Histogenics by 54.8% in the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 85,800 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Histogenics in the first quarter valued at approximately $320,000. Institutional investors own 43.21% of the company’s stock.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.